Troubled pharmaceuticals firm Ranbaxy reported its fourth-quarter earnings, posting a Rs 159-crore loss, chiefly driven by a Rs 257.4 crore write-off resulting from issues at its Toansa plant.In January, the US FDA banned imports from the company’s Toansa unit in Punjab over issues of quality control and data management issues.In a conference call, the company, now owned by Japanese Daiichi Sankyo, said it was committed to resolving issues with the FDA, which has now banned imports from all four its plants in India.Here are five key takeaways from the call.- The company has met all commitments it made to the FDA for its Mohali plant and that remediation, or action the company has taken on issues brought up, was on track.- Ranbaxy is in “advanced investigation” stage over findings of the FDA and has submitted its responses to the US drug regulator.- Only about 10-12 percent of its US sales were dependent on products from its Taonsa unit.- Sales grew in most of the firm’s major markets such as US, India and Eastern Europe.- Ranbaxy started a new entity in Thailand where the company and its parent Daiichi are in the process of integrating their business operations.- The company filed three abbreviated new drug applications (ANDAs) in the US market, where drugs are currently being supplied from its New Jersey unit.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
